title: Possibilities of formoterol to enhance the peripheral lung deposition of the inhaled liposome corticosteroids.
abstract: The pulmonary distribution and clearance of 99m-Tc-labelled beclomethasone dipropionate (Bec)--dilauroylphosphatidylcholine (DLPC) were compared in nine asthmatic patients on inhaled steroids after a 1-week medical treatment period of long-acting beta2-agonist formoterol. The patients were given formoterol 12 microg (OxisTurbuhaler) twice daily in addition to their own regular inhaled corticosteroid therapy. Gamma lung scintigraphy and lung function tests were performed before and after formoterol treatment. The bronchodilating effect ofthe combined therapy was significant: 1-week usage of inhaled formoterol enhanced peripheral lung deposition of beclomethasone liposome and thus diminished central/peripheral deposition ratio (C/P ratio). All measured lung function values except FEV1/FVC% improved after the medication period, although statistically significant levels were not reached. A systemic positive connection was seen between enhanced lung functions and greater lung deposition measured as AUC(0-24h)/24 Beclomethasone liposome formulation maintained its long-lasting effect in connection with formoterol treatment. At the 4-h measurement, 76% of the liposome-entrapped radioactivity still remained in the lungs before and 75% after the medication period.
authors.affiliation: Department of Respiratory Medicine, Tampere University Hospital, Tampere, Finland. marisanna.saari@tays.fi
authors.forename: S M
authors.initials: SM
authors.lastname: Saari
authors.forename: M T
authors.initials: MT
authors.lastname: Vidgren
authors.forename: J
authors.initials: J
authors.lastname: Herrala
authors.forename: V M H
authors.initials: VM
authors.lastname: Turjanmaa
authors.forename: M O
authors.initials: MO
authors.lastname: Koskinen
authors.forename: M M
authors.initials: MM
authors.lastname: Nieminen
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D001249:Asthma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001507:Beclomethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D000068759:Formoterol Fumarate; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008081:Liposomes; D008168:Lung / Q000000981:diagnostic imaging / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009079:Mucociliary Clearance; D011877:Radionuclide Imaging; D012129:Respiratory Function Tests; D013667:Technetium; D013997:Time Factors
chemical_list: D001993:Bronchodilator Agents; D004983:Ethanolamines; D005938:Glucocorticoids; D008081:Liposomes; D013667:Technetium; D001507:Beclomethasone; D000068759:Formoterol Fumarate